Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• In the ASCT-eligible group, the 1-year progression-free survival (PFS) rate for CAR T-cell therapy was 0.40 (95% CI (Confidence interval), 0.15 to 0.65), while for chemotherapy followed by ASCT, it was 0.34 (95% CI, 0.30 to 0.37). There was no significant difference in effectiveness between these two treatments.
• In the ASCT-ineligible group, CAR T-cell therapy had a 1-year PFS rate of 0.40 (95% CI, 0.35 to 0.46), while the tafasitamab group showed a 1-year PFS rate of 0.47 (95% CI, 0.37 to 0.57). CAR T-cell therapy demonstrated better outcomes than chemotherapy and therapies involving ibrutinib, lenalidomide, and selinexor. However, there was no significant difference in effectiveness between CAR T-cell therapy and loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group.
• The study does not provide specific safety information regarding loncastuximab tesirine-lpyl (Zynlonta) or the other drugs mentioned. Therefore, no detailed safety outcomes are available for synthesis in this section.
• The study examined two key groups: ASCT-eligible and ASCT-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). In the ASCT-eligible group, CAR T-cell therapy and chemotherapy followed by ASCT showed no significant difference in 1-year progression-free survival (PFS). In the ASCT-ineligible group, CAR T-cell therapy demonstrated significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor, but was comparable in effectiveness to loncastuximab, polatuzumab plus bendamustine and rituximab, and tafasitamab.